Current and emerging pharmacotherapeutic options for irritable bowel syndrome

  • Barboza J
  • Talley N
  • Moshiree B
  • 33

    Readers

    Mendeley users who have this article in their library.
  • 10

    Citations

    Citations of this article.

Abstract

Abstract Treatment of irritable bowel syndrome (IBS) is\r
challenging for both primary care physicians and gastroenterologists\r
because of the heterogeneity of the patient\r
population and the multifactorial pathophysiologies\r
responsible for the symptoms in IBS. This review focuses\r
on the current and emerging pharmacological treatments\r
for IBS. Many of the current medications used to treat this\r
disorder have distinct properties such as efficacy for different\r
symptoms, safety profiles, contraindications, costs,\r
dosing regimens, treatment duration and long-term data.\r
All of these factors, in addition to patient preference and\r
cognitive, food and environmental triggers, must be considered\r
prior to any medication selection. This review will\r
focus on randomized controlled trials with a general uniformity\r
in study design, a rigorous patient selection and\r
appropriate treatment durations. We will also discuss other\r
exciting emerging treatments for IBS such as the l-opioid\r
receptor (agonists and antagonists), selective j-opioid\r
receptor agonists, anti-inflammatory drugs, serotonergic\r
agents, bile acid modulators and intestinal bile acid\r
transporters, which may prove promising in treating our\r
patients.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Jose L. Barboza

  • Nicholas J. Talley

  • Baharak Moshiree

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free